Control activity while reducing steroid harm. JIA guidance and trial results apply to defined populations; persistent activity or sight-threatening complications may require earlier systemic treatment rather than a rigid waiting period.
Terminology and draft status
Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.
01Coordinate the child’s whole care
Many noninfectious forms accompany juvenile idiopathic arthritis (JIA) or another systemic disorder. Ocular and joint disease can share mechanisms, but treating one does not reliably prevent the other, and an association is not proof of cause. 1 3
Rheumatology helps select and monitor systemic immunosuppression, while ophthalmology retains responsibility for activity, complications and visual function. The original recommends rheumatology review for every child; referral is especially important for suspected systemic disease or systemic treatment and should fit the clinical cause. 1 3
Long-term care burdens families psychologically and logistically. Specialist nurses, doctors and an accessible contact help with adverse effects, medicine adjustments and regular blood tests; explain who handles urgent symptoms and who reviews results. 1
02Use the history to challenge the first label
Ask about onset, unilateral or bilateral disease, previous red-eye episodes even in early childhood, morning joint pain or altered gait, rash, oral ulcers, chronic diarrhoea, weight loss and malaise. Clarify the timing and nature of trauma; an event preceding symptoms does not prove causation. 1
In the original teaching case, an 18-year-old referred for presumed Behçet disease and methotrexate had recurrent unilateral inflammation since age 7. The history redirected assessment toward herpetic keratitis. This is an unverified illustrative record: unilateral recurrence raises an infectious differential but does not alone confirm herpes or exclude Behçet disease. 1
A second original case describes a 14-year-old whose retinal detachment was attributed to a football injury 2 months earlier. Fellow-eye inflammation and macular oedema led to a diagnosis of intermediate uveitis after the first eye had lost vision. The record does not establish that the outcome was preventable. Examine both eyes and reconsider an inadequate trauma explanation. 1
03Classify the cause before selecting treatment
Separate noninfectious, infectious and masquerade causes as in the table. JIA, idiopathic disease, inflammatory bowel disease (IBD), sarcoidosis/Blau syndrome, TINU, pars planitis and Behçet disease do not share one diagnostic test or one treatment pathway. 1
The original assigns JIA 40–60% and IBD 2–12%, and describes toxocariasis as relatively common in the UK. Populations, denominators and primary sources are unresolved; these are original teaching estimates, not universal proportions or a reason to omit infection. 1
Consider toxoplasmosis, toxocariasis, HSV, VZV, CMV, EBV, syphilis, TB and geographically relevant Lyme disease. Atypical hypopyon or poor response also raises retinoblastoma, leukaemia or lymphoma; lack of response alone does not identify which cause is present. 1
| Category | Condition | Interpretation |
|---|---|---|
| Noninfectious | JIA | Original 40–60%: population/denominator unverified; ANA informs risk. |
| Noninfectious (continued category) | Idiopathic | Diagnosis after appropriate exclusion, not after every conceivable test. |
| Noninfectious | IBD: Crohn disease, ulcerative colitis | Original 2–12% denominator unresolved; often anterior disease. |
| Noninfectious | Sarcoidosis / Blau syndrome | Consider systemic findings and genetic context; not every sarcoidosis is Blau syndrome. |
| Noninfectious | TINU | Tubulointerstitial nephritis and uveitis; urine and renal assessment may guide diagnosis. |
| Noninfectious | Pars planitis / intermediate uveitis | Pars planitis is an idiopathic subset, not every intermediate case; macular oedema matters. |
| Noninfectious | Behçet disease | Uncommon in children; posterior/panuveitic involvement can be severe. |
| Infectious | Toxoplasmosis, toxocariasis | Regional exposure matters; the original UK frequency assertion is unverified. |
| Infectious (continued category) | HSV, VZV, CMV, EBV | Consider especially unilateral disease; clinical context and selected testing determine relevance. |
| Infectious | Syphilis, TB, Lyme disease | History, geography and treatment context guide testing; a negative single test is not comprehensive exclusion. |
| Masquerade | Retinoblastoma, leukaemia/lymphoma | Atypical course, hypopyon or nonresponse need urgent reassessment. |
04Investigate a question, not an indiscriminate panel
The original first-line panel includes CRP/ESR, blood count, liver and renal function, ANA, HLA-B27 and urine dipstick. Select tests by phenotype and treatment plans: inflammatory markers may be normal, a normal blood count does not exclude malignancy, and urine/renal results contribute to rather than independently exclude TINU. 1
ANA helps JIA risk stratification; HLA-B27 is more informative with a compatible older-child or spondyloarthritis phenotype. ACE and chest imaging for suspected sarcoidosis, ASO after a compatible infection and selected toxoplasma/toxocara/syphilis/HIV/Borrelia tests need clinical interpretation; positivity is not automatically the ocular diagnosis. 1
Assess TB exposure and active versus latent infection before biologic treatment; an isolated negative IGRA does not exclude every ocular infection. In unclear selected cases, specialist anterior-chamber sampling or vitrectomy may provide HSV/VZV/CMV PCR or cytology; coordinate indication, volume, transport and laboratory tests beforehand. 1 5
05Suppress inflammation without accepting chronic steroid harm
For selected noninfectious anterior uveitis, intensive topical corticosteroid followed by an activity-guided taper is standard; the original every 1–2 hours is an example, not a regimen for every cause. Monitor pressure, cataract and infection, and do not call a twice-daily maintenance dose universally safe. 1 3
Systemic oral or IV steroids may be used as a short bridge for selected severe, intermediate/posterior or otherwise inadequately controlled noninfectious disease. Bilaterality alone is not an indication; plan steroid-sparing control rather than prolonged systemic steroid dependence. 1 3
Methotrexate is a common first systemic DMARD for JIA-associated chronic anterior uveitis; response may take up to 3 months, with earlier reassessment for sight threat. ACR conditionally favours subcutaneous over oral treatment, with weak comparative evidence and family preference considered; better gastrointestinal tolerance is not guaranteed for every child. 1 3
06Match biologic treatment to evidence and indication
Adalimumab or infliximab, monoclonal anti-TNF agents, may be selected for refractory JIA-associated disease; severe sight-threatening disease can justify early combination treatment rather than waiting for sequential failure. The original 30–40% methotrexate-failure estimate lacks a defined source/population; tocilizumab, an IL-6 inhibitor, remains a selected specialist option rather than a universal next step for macular oedema. 1 3
SYCAMORE randomised children aged at least 2 with active JIA uveitis on stable methotrexate to adalimumab or placebo. Failure occurred in 16/60 versus 18/30, with hazard ratio 0.25 (95% CI 0.12–0.49); early stopping and more adverse events with adalimumab matter when applying the result. It does not prove benefit for infectious uveitis or every paediatric diagnosis. 4
EU product information limits the paediatric adalimumab indication to chronic noninfectious anterior uveitis from age 2 after inadequate response, intolerance or inappropriateness of conventional treatment. Infliximab is an IV option with its own local/off-label considerations; check the exact product and current jurisdiction instead of describing all childhood uveitis as licensed. 5
Methotrexate can reduce immunogenicity of monoclonal biologics and is often combined when tolerated, but “always” is too absolute. The original Syrian example warns about interrupted or inadequate dosing; without its records it cannot establish that interrupted treatment is invariably worse than none or that loss of response is permanent. Address access, adherence, safety and specialist review without blaming families. 1 3 4
07Define inactivity and decide when to escalate
SUN anterior-chamber inactivity is grade 0, fewer than 1 cell in a 1x1 mm field; 0.5+ is not inactive. The original adapted control target of at most 0.5+, no vitreous haze or active retinal lesions, no new complications and stable/improved acuity is a proposed management composite, not the SUN definition. 1 2
The original also seeks control without systemic steroids and with no more than 2 topical drops daily. Steroid dependence remains important even below that threshold: ACR JIA guidance considers systemic addition or change when 1–2 daily drops remain necessary for at least 3 months, with earlier action for activity or complications. This is not permission to leave an eye inflamed until a deadline. 1 3
Persistent activity, relapse on taper, steroid toxicity or new/worsening macular oedema, glaucoma or cataract can trigger escalation. Original thresholds of more than 1+ cells for 3 months or more than 2 daily drops/systemic steroids beyond 3 months are not universal minimum waits. An only seeing eye increases the urgency of a specialist, individualised plan. 1 3
08Treat complications within the inflammatory plan
For raised pressure, distinguish steroid response, inflammation and angle damage and involve glaucoma expertise early. The original favours beta-blockers and carbonic-anhydrase inhibitors and avoids pilocarpine/prostaglandins; select medicines by age, contraindications, activity and macular/viral context rather than treating every prostaglandin as absolutely forbidden. 1
Elective uveitic cataract surgery generally aims for sustained quiescence; the original at least 3-month target is a planning principle, with timing individualised for amblyopia and urgency. Plan perioperative anti-inflammatory cover, IOL/capsule management and, in selected younger children, posterior capsulotomy with anterior vitrectomy; these are not automatic steps for every age or infection. 1
Cystoid macular oedema threatens vision and warrants assessment of inflammatory activity, infection, traction and other causes. It may require systemic escalation for noninfectious disease, but its appearance alone does not mandate the same immunosuppressive regimen for every child; follow OCT, function and the child’s whole course. 1
What are the main learning points?
Control activity while reducing steroid harm. JIA guidance and trial results apply to defined populations; persistent activity or sight-threatening complications may require earlier systemic treatment rather than a rigid waiting period.
When is assessment urgent?
Sudden visual loss, severe pain, new field loss, marked inflammation or pressure rise needs urgent ophthalmic assessment. Suspected infection, neurological disease or malignancy requires a coordinated urgent pathway before immunosuppression is assumed appropriate.
References and access status
- 1Immutable original export; original paediatric uveitis lecture; attribution unchecked
Complete export read; original attribution and any recording/transcript or appointment not independently verified.
- 2SUN 2005 nomenclature and grading
Parent read tables 1–5 and selected definition text on 10 November 2026 during review 080; reused with scope, not a new full-report appraisal.
- 3ACR/AF 2019 guideline for JIA-associated uveitis
Selected table 3/recommendations read earlier on 10 November 2026 in review 080; new indexed recommendation 10/11 and monitoring extracts inspected. Current direct/alternate full-text attempts blocked or returned non-XML; not a complete new guideline reading.
- 4SYCAMORE. Adalimumab plus methotrexate. 2017
Complete NCBI abstract read 10 November 2026: randomised JIA population, early stop and adverse events; complete trial report/protocol/supplement not appraised.
- 5EMA Humira product information: paediatric indication
Selected indexed indication text at printed page 106 inspected 10 November 2026; 2017 variation assessment selected text inspected separately. Complete current dosing/safety/product information not appraised; no universal paediatric indication or dose inference.
Original lecture link
For patients
Eye inflammation may accompany joint, skin, bowel or kidney disease, but infection and other causes also occur. The family needs a named contact, a clear monitoring plan and support with medicines, travel and appointments.
Examination and selected tests guide individual treatment and follow-up; this educational text cannot replace your own assessment.
Sudden visual loss, severe pain, new field loss, marked inflammation or pressure rise needs urgent ophthalmic assessment. Suspected infection, neurological disease or malignancy requires a coordinated urgent pathway before immunosuppression is assumed appropriate.
Sudden visual loss, severe pain, new field loss, marked inflammation or pressure rise needs urgent ophthalmic assessment. Suspected infection, neurological disease or malignancy requires a coordinated urgent pathway before immunosuppression is assumed appropriate.